Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Cosentyx
Pharma
Novartis increases sales growth estimate through 2029
Backed by the momentum of its current growth drivers, Novartis has adjusted its growth rate expectation from 5%-plus to 6%-plus through 2029.
Kevin Dunleavy
Nov 21, 2024 11:57am
UCB tallies another FDA nod for blockbuster hopeful Bimzelx
Nov 20, 2024 10:44am
Biologics gaining ground in HS, but more support needed: Spherix
Nov 11, 2024 11:52am
Swiss antitrust regulator drops investigation against Novartis
Oct 10, 2024 9:46am
Novartis' celebrity standbys report Cosentyx is 'Still Working'
May 17, 2024 4:26pm
Novartis gears up for key expansions of 3 cancer drugs
Apr 23, 2024 3:37pm
